Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay®) on glycaemic control in type 1 and type 2 diabetes patients

Randomised Controlled ◽

The Impact ◽

Diabetes Patients

The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study

Clinical Nutrition ESPEN ◽

10.1016/j.clnesp.2020.07.002 ◽

2020 ◽

Vol 39 ◽

pp. 46-52

Author(s):

Mads N. Thomsen ◽

Mads J. Skytte ◽

Arne Astrup ◽

Carolyn F. Deacon ◽

Jens J. Holst ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

High Protein Diet ◽

Controlled Study ◽

Clinical Effects ◽

Glycaemic Variability ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review5 ◽

2019 ◽

Author(s):

Christine Mermier

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/review2 ◽

2019 ◽

Author(s):

Christine Mermier

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

Yearbook of Endocrinology ◽

10.1016/s0084-3741(08)70088-x ◽

2007 ◽

Vol 2007 ◽

pp. 150-154

Author(s):

D.H. Bessesen

Keyword(s):

Type 2 Diabetes ◽

Controlled Study ◽

Obese Patients ◽

Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit

Diabetic Medicine ◽

10.1111/dme.13062 ◽

2016 ◽

Vol 33 (11) ◽

pp. 1575-1581 ◽

Cited By ~ 58

Author(s):

M. Baxter ◽

R. Hudson ◽

J. Mahon ◽

C. Bartlett ◽

Y. Samyshkin ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Financial Benefit ◽

Clinical Complications ◽

The Impact

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study

Yearbook of Obstetrics Gynecology and Women s Health ◽

10.1016/j.yobg.2011.05.175 ◽

2011 ◽

Vol 2011 ◽

pp. 15-16

Author(s):

J.S. Dungan

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Low Dose ◽

Controlled Study ◽

Double Blind ◽

Dose Combination ◽

Effect of a pharmacist-led educational intervention on clinical outcomes: a randomised controlled study in patients with hypertension, type 2 diabetes and hypercholesterolaemia

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2021-002787 ◽

2021 ◽

pp. ejhpharm-2021-002787

Author(s):

Clement Delage ◽

Hélène Lelong ◽

Francoise Brion ◽

Jacques Blacher

Keyword(s):

Type 2 Diabetes ◽

Clinical Outcomes ◽

Educational Intervention ◽

Controlled Study ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/review3 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v2/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽

Review for "Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomised controlled study (PRIME‐V study)"

10.1111/dom.13750/v1/review2 ◽

2019 ◽

Author(s):

Zhengxiang Huang

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Japanese Patients ◽

Controlled Study ◽

Metabolic Dysfunction ◽

Open Label ◽

Fat Reduction ◽